Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Sep;40(3):245–251. doi: 10.1111/j.1365-2125.1995.tb05780.x

A comparison of the contractile effects of 5-hydroxytryptamine, sumatriptan and MK-462 on human coronary artery in vitro.

A Ferro 1, J Longmore 1, R G Hill 1, M J Brown 1
PMCID: PMC1365104  PMID: 8527286

Abstract

1. MK-462 (N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H- indol-3-yl]ethylamine) is a novel selective 5-HT1D-receptor agonist which in clinical trials has been shown to be an effective antimigraine agent. As angiographic studies have shown that sumatriptan (an established 5-HT1D-receptor agonist) can cause coronary artery vasoconstriction in patients, we compared the effects of MK-462 with those of 5-HT and those of sumatriptan, on isolated segments of human coronary artery in vitro. 2. Coronary arteries were obtained from explanted hearts from patients (n = 22, 2 females, 20 males, aged 21-60 years) undergoing cardiac transplantation. Endothelium-denuded ring segments of coronary artery, 2mm long were mounted in organbaths for isometric tension recording. For each arterial ring segment, a cumulative concentration-effect curve to either 5-HT, sumatriptan or MK-462 was determined. After maximal response to each agonist had been obtained, ketanserin (a 5-HT2 receptor antagonist) 0.6 microM was added to the tissue bath, followed by methiotepin (0.6 microM) and the reduction in tension produced by the addition of each antagonist was determined. 3. Out of 22 coronary arteries studied, only 10 showed any response (contraction) to 5-HT. Not all arteries which responded to 5-HT contracted in response to both sumatriptan and MK-462 (one ring from each artery being exposed to a single agonist in each case).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
250

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berkenboom G., Unger P., Fang Z. Y., Degre S., Fontaine J. Comparison of responses to acetylcholine and serotonin on isolated canine and human coronary arteries. Cardiovasc Res. 1989 Sep;23(9):780–787. doi: 10.1093/cvr/23.9.780. [DOI] [PubMed] [Google Scholar]
  2. Chester A. H., Martin G. R., Bodelsson M., Arneklo-Nobin B., Tadjkarimi S., Tornebrandt K., Yacoub M. H. 5-Hydroxytryptamine receptor profile in healthy and diseased human epicardial coronary arteries. Cardiovasc Res. 1990 Nov;24(11):932–937. doi: 10.1093/cvr/24.11.932. [DOI] [PubMed] [Google Scholar]
  3. Cocks T. M., Kemp B. K., Pruneau D., Angus J. A. Comparison of contractile responses to 5-hydroxytryptamine and sumatriptan in human isolated coronary artery: synergy with the thromboxane A2-receptor agonist, U46619. Br J Pharmacol. 1993 Sep;110(1):360–368. doi: 10.1111/j.1476-5381.1993.tb13818.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Connor H. E., Feniuk W., Humphrey P. P. 5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation. Eur J Pharmacol. 1989 Feb 14;161(1):91–94. doi: 10.1016/0014-2999(89)90184-2. [DOI] [PubMed] [Google Scholar]
  5. Golino P., Piscione F., Benedict C. R., Anderson H. V., Cappelli-Bigazzi M., Indolfi C., Condorelli M., Chiariello M., Willerson J. T. Local effect of serotonin released during coronary angioplasty. N Engl J Med. 1994 Feb 24;330(8):523–528. doi: 10.1056/NEJM199402243300802. [DOI] [PubMed] [Google Scholar]
  6. Golino P., Piscione F., Willerson J. T., Cappelli-Bigazzi M., Focaccio A., Villari B., Indolfi C., Russolillo E., Condorelli M., Chiariello M. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med. 1991 Mar 7;324(10):641–648. doi: 10.1056/NEJM199103073241001. [DOI] [PubMed] [Google Scholar]
  7. Humphrey P. P., Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci. 1991 Dec;12(12):444–446. doi: 10.1016/0165-6147(91)90630-b. [DOI] [PubMed] [Google Scholar]
  8. Humphrey P. P., Feniuk W., Perren M. J., Connor H. E., Oxford A. W. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia. 1989;9 (Suppl 9):23–33. doi: 10.1111/J.1468-2982.1989.TB00069.X. [DOI] [PubMed] [Google Scholar]
  9. Ichikawa Y., Yokoyama M., Akita H., Fukuzaki H. Constriction of a large coronary artery contributes to serotonin-induced myocardial ischemia in the dog with pliable coronary stenosis. J Am Coll Cardiol. 1989 Aug;14(2):449–461. doi: 10.1016/0735-1097(89)90201-5. [DOI] [PubMed] [Google Scholar]
  10. Kaumann A. J., Frenken M., Posival H., Brown A. M. Variable participation of 5-HT1-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT1-like receptors resemble cloned 5-HT1D beta receptors. Circulation. 1994 Sep;90(3):1141–1153. doi: 10.1161/01.cir.90.3.1141. [DOI] [PubMed] [Google Scholar]
  11. Lloyd D. K., Simmons V. Adverse reactions associated with sumatriptan. Lancet. 1993 Apr 24;341(8852):1092–1092. [PubMed] [Google Scholar]
  12. Macintyre P. D., Bhargava B., Hogg K. J., Gemmill J. D., Hillis W. S. The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol. 1992 Dec;34(6):541–546. [PMC free article] [PubMed] [Google Scholar]
  13. Martin G. R., MacLennan S. J. Analysis of the 5-HT receptor in rabbit saphenous vein exemplifies the problems of using exclusion criteria for receptor classification. Naunyn Schmiedebergs Arch Pharmacol. 1990 Aug;342(2):111–119. doi: 10.1007/BF00166952. [DOI] [PubMed] [Google Scholar]
  14. McFadden E. P., Clarke J. G., Davies G. J., Kaski J. C., Haider A. W., Maseri A. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med. 1991 Mar 7;324(10):648–654. doi: 10.1056/NEJM199103073241002. [DOI] [PubMed] [Google Scholar]
  15. Ottervanger J. P., Paalman H. J., Boxma G. L., Stricker B. H. Transmural myocardial infarction with sumatriptan. Lancet. 1993 Apr 3;341(8849):861–862. doi: 10.1016/0140-6736(93)93064-8. [DOI] [PubMed] [Google Scholar]
  16. Saxena P. R., Ferrari M. D. 5-HT(1)-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci. 1989 May;10(5):200–204. doi: 10.1016/0165-6147(89)90238-1. [DOI] [PubMed] [Google Scholar]
  17. Sumner M. J., Feniuk W., McCormick J. D., Humphrey P. P. Studies on the mechanism of 5-HT1 receptor-induced smooth muscle contraction in dog saphenous vein. Br J Pharmacol. 1992 Mar;105(3):603–608. doi: 10.1111/j.1476-5381.1992.tb09026.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Toda N., Okamura T. Comparison of the response to 5-carboxamidotryptamine and serotonin in isolated human, monkey and dog coronary arteries. J Pharmacol Exp Ther. 1990 May;253(2):676–682. [PubMed] [Google Scholar]
  19. Willett F., Curzen N., Adams J., Armitage M. Coronary vasospasm induced by subcutaneous sumatriptan. BMJ. 1992 May 30;304(6839):1415–1415. doi: 10.1136/bmj.304.6839.1415. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES